FY2024 Earnings Forecast for VYGR Issued By HC Wainwright

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - HC Wainwright upped their FY2024 EPS estimates for Voyager Therapeutics in a report issued on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.82) per share for the year, up from their previous forecast of ($0.97). HC Wainwright currently has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Voyager Therapeutics' Q2 2025 earnings at ($0.31) EPS, FY2026 earnings at ($1.38) EPS, FY2027 earnings at ($1.32) EPS and FY2028 earnings at ($1.69) EPS.

VYGR has been the topic of a number of other reports. Leerink Partnrs raised shares of Voyager Therapeutics to a "strong-buy" rating in a research report on Wednesday, October 16th. StockNews.com raised Voyager Therapeutics from a "hold" rating to a "buy" rating in a report on Monday. Canaccord Genuity Group reaffirmed a "buy" rating and set a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday. Wedbush decreased their price objective on shares of Voyager Therapeutics from $8.00 to $7.00 and set a "neutral" rating for the company in a report on Wednesday, August 7th. Finally, Leerink Partners began coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an "outperform" rating and a $15.00 target price on the stock. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $17.00.

Voyager Therapeutics Stock Performance

Shares of NASDAQ VYGR traded down $0.25 during mid-day trading on Monday, hitting $5.39. 573,327 shares of the stock traded hands, compared to its average volume of 642,892. The company has a market cap of $294.18 million, a price-to-earnings ratio of 7.59 and a beta of 0.89. The stock has a fifty day moving average price of $6.62 and a 200-day moving average price of $7.49. Voyager Therapeutics has a 52 week low of $5.38 and a 52 week high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.29. The firm had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the prior year, the firm posted ($0.59) earnings per share.

Insider Buying and Selling at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm's stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now owns 86,001 shares of the company's stock, valued at $500,525.82. This trade represents a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.53% of the stock is owned by corporate insiders.

Institutional Trading of Voyager Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. raised its holdings in Voyager Therapeutics by 49.6% during the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company's stock valued at $37,000 after acquiring an additional 1,300 shares during the period. Victory Capital Management Inc. lifted its holdings in Voyager Therapeutics by 14.5% in the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company's stock worth $102,000 after purchasing an additional 1,630 shares in the last quarter. SummerHaven Investment Management LLC grew its holdings in Voyager Therapeutics by 2.5% during the 2nd quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company's stock valued at $611,000 after buying an additional 1,921 shares in the last quarter. Hunter Perkins Capital Management LLC raised its position in shares of Voyager Therapeutics by 3.3% during the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company's stock valued at $375,000 after buying an additional 2,025 shares during the last quarter. Finally, Empowered Funds LLC boosted its position in shares of Voyager Therapeutics by 5.4% during the third quarter. Empowered Funds LLC now owns 44,809 shares of the company's stock worth $262,000 after acquiring an additional 2,278 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.